AB1135

THE MANAGEMENT OF INTERSTITIAL LUNG DISEASES: THE IMPORTANCE OF THE RHEUMATOLOGIC EXPERTISE IN MULTIDISCIPLINARY MEETINGS

Enrico De Lorenzo1, Gerlando Natalelo1, Lucrezia Verard1, Silvia Laura Bosello2, Elisa Gremente1,2,3

1Catholic University of the Sacred Heart, Institute of Rheumatology, Rome, Italy; 2Fondazione PoliClinico Universitario A. Gemelli IRCCS, Department of Rheumatology, Rome, Italy

Background: Multidisciplinary Team (MDT) meetings are the current “gold standard” in interstitial lung disease (ILD) diagnosis. Requisite participants are respiratory physicians, radiologists and pathologists. A rheumatologist is not routinely involved in MDT even if up to 20% of ILD are related to connective tissue disease, rheumatoid arthritis or systemic vasculitis.

Objectives: The aim of this study is to evaluate the prevalence and predictors of systematic rheumatological diseases in a cohort of patients with ILD, evaluated by a rheumatology specialist on the advice of MDT in a university hospital.

Methods: Thirty-two patients with ILD, evaluated at dedicated MDT were referred to a rheumatologist in 2018, usually for autoantibodies positivity or clinical history suspected for a rheumatological disorder. Rheumatological evaluation included physical examination, routine blood and urine tests, serum levels of C3 and C4, ANA, Rheumatoid Factor (RF), ANCA, anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB, anti-Sm, anti-Jo1, anti-dsDNA and anti-CCP antibodies. Family history of autoimmune diseases, presence of rheumatological red flag, routine laboratory abnormalities, ANA, RF, or clinical history suspected for a rheumatological disorder. Rheumatological participation of rheumatologist to MDT is advisable to increase accuracy and reduce delay in diagnosis and treatment.

Disclosure of Interests: None declared


AB1136

CD26: A POTENTIAL NOVEL HISTOLOGICAL MARKER OF IDIOPATHIC INFLAMMATORY MYOPATHIES

Rebecca De Lorenzo1,2, Clara Sciorti1, Antonio Monno1, Francisco Bonomo1, Silvia Cavali1, Antonio Francesco Di Naro1, Stefano Previtali1, Patricia Rovere-Querini3,4,5,6,7,8

1Catholic University of the Sacred Heart, Institute of Rheumatology, Rome, Italy; 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Rheumatology, Rome, Italy

Background: Idiopathic inflammatory myopathies (IM) are a heterogeneous group of acquired skeletal muscle disorders including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM) and immune-mediated necrotising myopathy (IMNM), characterized by immune-mediated muscle damage. Activated T cells are the predominant inflammatory infiltrates in muscle biopsies of PM and DM patients and the lack of T regulatory cells (Treg) has been implicated in the persistence of muscle damage. CD26 is an intrinsic membrane glycoprotein and a serine exopeptidase involved in the activation of T lymphocytes and amplification of inflammatory cytokines production. The enzymatically active form of CD26 is selectively expressed by activated T cells and has been described as a negative selective marker for human Treg.

Objectives: The aims of this study were to evaluate the expression, regulation and co-localization of CD26 in muscle biopsies of IM patients and to correlate it with patients’ clinical and histological features.

Methods: Immunofluorescence was used to evaluate CD26 expression and co-localization with CD3 and CD31, markers of T cells and endothelial cells respectively, in muscle biopsies of 6 DM, 6 PM, 3 IBM and 3 IMNM patients and of 6 healthy controls.

Results: We found that CD26 is preferentially expressed in muscle biopsies of IIM patients with respect to controls and that its level of expression is higher in DM patients. In muscle biopsies of IIM patients, CD26 is distributed not only in the extracellular matrix surrounding myofibers and infiltrating leukocytes, but also at the level of T cell membranes and endothelial cells. Specifically, CD26 co-localization with CD31 is more prominent in DM muscle biopsies. We could not find any association between vessel morphology in terms of size and shape and CD26 endothelial expression, suggesting that CD26 is expressed at the perivascular level independently of the degree of vessel dysfunction. With regard to clinical features, we found that CD26 is more expressed in patients presenting the typical DM rash. Moreover, CD26 expression was found not to be significantly associated with the degree of muscle weakness nor with the presence of interstitial lung disease, dysphagia, myalgias or mechanic’s hands. As for histological data, higher levels of CD26 expression were found in biopsies with perivascular inflammatory infiltrates, especially T lymphocytes and macrophages.

Conclusion: Our data suggest that CD26 may represent a suitable marker for the diagnosis of IIM and a potential novel target for selective immune-therapies.

Disclosure of Interests: None declared


REFERENCES


AB1137 QUANTIFYING KNEE JOINT EFFUSIONS WITH CLINICAL TESTS, MUSCULOSKELTAL ULTRASOUND AND SYNOVIAL FLUID ASPIRATION: A PROSPECTIVE COHORT STUDY

Thilinie De Silva1, Chris Pham2, Adam Rischin2, Kim Le Marshall 1,3, Sara Vogrin4, Lucie Demaria, Raphael Borie, Khadija Benali, Marine Forien, Philippe Dieudé, Bruno Crestani, Sebastien Ottaviani, Bichat-Claude Bernard Hospital, Paris, France

Background: Aspiration of knee joint effusions is an integral diagnostic approach. The accuracy of these tests for determining effusion presence and size is not well established. Musculoskeletal ultrasound (MUS) is considered better for identification and quantification of knee effusions. Objectives: To investigate the correlation between both clinical examination and MUS to aspirated knee effusion volume.

Methods: We performed a prospective cohort study of 37 osteoarthritis patients with symptomatic knee effusions. Clinical assessment with patella tap, bulge test and knee circumference measurement were carried out. MUS was used to measure effusion depth in the suprapatellar, lateral and medial parapatellar views. All knee effusion aspirations were performed by the same experienced clinician using a consistent, lateral approach. Linear regression analysis was used to assess correlations between clinical tests, MUS and aspiration volume.

Results: In patients with >3ml of fluid aspirated, patella tap and bulge test were positive in 67% and 80% respectively. The positive predictive value for bulge test was 80%. Where larger volumes were aspirated (i.e. >10ml), patella tap and bulge test were only positive in 52% and 65% respectively. There was a significant correlation between the measured circumference of the index knee and aspiration of fluid (coefficient=1.57, p=0.06). The relationship between fluid depth on MUS and aspirated volume showed a trend towards statistical significance, with a depth of 1mm equating to 1.57 ml of fluid (coefficient=1.57, p=0.06).

Conclusion: This pilot study demonstrates that a positive patella tap or bulge test is moderately predictive of knee effusion volume. However, this association is weaker when larger knee effusions are present. MUS showed promise at accurately predicting knee effusion volume. A larger study is underway to assess this relationship further.

Disclosure of Interests: Thilinie De Silva: None declared, Chris Pham: None declared, Adam Rischin: None declared, Kim Le Marshall: None declared, Sara Vogrin: None declared, Albert Leung: None declared, Keith Lim Consultant for: Advisor for role of hepatitis and TB in Cimzia, UCB, Speakers bureau: Role of biological in pregnancy UCB


AB1138 BONE SARCOIDOSIS: USEFULNESS OF 18F-FDG PET/CT

Lucie Demaria, Raphael Borie, Khadija Benali, Marine Forien, Philippe Dieudé, Bruno Crestani, Sebastien Ottaviani, Bichat-Claude Bernard Hospital, Paris, France

Background: Bone sarcoidosis is usually rare but more sensitive imaging procedures such as 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) allow a better characterization of such lesions. We aimed to describe bone sarcoidosis involvement using 18F-FDG PET/CT.

Objectives: To perform an observational retrospective study of patients with pulmonary sarcoidosis having a 18F-FDG PET/CT. As stated by ATS/ERS/WASOG criteria, diagnosis of sarcoidosis was established on the presence of clinical symptoms and/or imaging features of sarcoidosis, and evidence of non-caseating epithelioid granuloma in a biopsy sample after exclusion of other known etiologies of granuloma. We assessed clinical and 18F-FDG PET/CT characteristics.

Methods: We performed an observational retrospective study of patients with pulmonary sarcoidosis having a 18F-FDG PET/CT. As stated by ATS/ERS/WASOG criteria, diagnosis of sarcoidosis was established in 12 (14%) patients. Spine was the most commonly affected bone (92%), followed by pelvis (67%), sternum (33%), humerus (25%) and fingers (17%). Only peripheral adenopathy was associated with bone lesions (p<0.04). Seven patients have benefited from a follow-up 18F-FDG PET/CT, which in 100% of cases showed an improvement of lesions.

Conclusion: Bone sarcoidosis occurred in 14% of patients, affecting multiple bones and mostly the axial skeleton. 18F-FDG PET/CT appears to be a sensitive imaging for diagnosis and follow-up of bone sarcoidosis.

Disclosure of Interests: None declared

REFERENCES

[3] Bechman K, and al. Rheumatology 1 mai 2018